Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRPR | P30550 | 8/20 | 0.61 |
| ▸ | CCKBR | P32239 | 3/20 | 0.54 |
| ▸ | GLP1R | P43220 | 3/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.53 |
| ▸ | NMBR | P28336 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30118089 | 0.93 | GRPR (0.65) | GRPRGLP1ROPRM1OPRD1 | |
| SCHEMBL2193571 | 0.91 | GRPR (0.67) | GRPRGLP1ROPRM1OPRD1NMBR | |
| SCHEMBL6510905 | 0.91 | GRPR (0.68) | GRPRGLP1ROPRM1OPRD1 | |
| SCHEMBL29663974 | 0.91 | GRPR (0.68) | GRPRGLP1ROPRM1OPRD1 | |
| SCHEMBL31069834 | 0.91 | GRPR (0.66) | GRPRGLP1RNMBR | |
| SCHEMBL29663793 | 0.89 | GRPR (0.61) | GRPRCCKBRGLP1ROPRM1OPRD1 | |
| SCHEMBL30118090 | 0.89 | GRPR (0.60) | GRPRGLP1ROPRM1OPRD1 | |
| SCHEMBL30118082 | 0.88 | GRPR (0.65) | GRPRGLP1R | |
| SCHEMBL38661265 | 0.88 | GRPR (0.65) | GRPRGLP1ROPRM1OPRD1NMBR | |
| SCHEMBL30628977 | 0.87 | GRPR (0.64) | GRPRGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366812-A1 | Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2024-11-07 | — | — | US | disclosed |
| US-12064489-B2 | Radiolabeled GRPR-antagonists for diagnostic imaging and treatment of GRPR-positive cancer | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2024-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366812-A1 | Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer | GRPR, GIPR, CCKBR | GRPR 1/4885CCKBR 3/4885GLP1R 7/4885 |
| US-12064489-B2 | Radiolabeled GRPR-antagonists for diagnostic imaging and treatment of GRPR-positive cancer | GRPR, GIPR, CCKBR | GRPR 1/4885CCKBR 3/4885GLP1R 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.